Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.

Details

Serval ID
serval:BIB_BDB3F09ECFB7
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.
Journal
Endothelium
Author(s)
Alghisi G.C., Rüegg C.
ISSN
1062-3329 (Print)
ISSN-L
1026-793X
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
13
Number
2
Pages
113-135
Language
english
Abstract
The notion that tumor angiogenesis may have therapeutic implications in the control of tumor growth was introduced by Dr. Judah Folkman in 1971. The approval of Avastin in 2004 as the first antiangiogenic systemic drug to treat cancer patients came as a validation of this visionary concept and opened new perspectives to the treatment of cancer. In addition, this success boosted the field to the quest for new therapeutic targets and antiangiogenic drugs. Preclinical and clinical evidence indicate that vascular integrins may be valid therapeutic targets. In preclinical studies, pharmacological inhibition of integrin function efficiently suppressed angiogenesis and inhibited tumor progression. alphaVbeta3 and alphaVbeta5 were the first vascular integrins targeted to suppress tumor angiogenesis. Subsequent experiments revealed that at least four additional integrins (i.e., alpha1beta1, alpha2beta1, alpha5beta1, and alpha6beta4) might be potential therapeutic targets. In clinical studies low-molecular-weight integrin inhibitors and anti-integrin function-blocking antibodies demonstrated low toxicity and good tolerability and are now being tested in combination with radiotherapy and chemotherapy for anticancer activity in patients. In this article the authors review the role of integrins in angiogenesis, present recent development in the use of alphaVbeta3 and alpha5beta1 integrin antagonists as potential therapeutics in cancer, and discuss future perspectives.
Keywords
Animals, Clinical Trials as Topic, Endothelial Cells/pathology, Humans, Integrins/antagonists & inhibitors, Integrins/physiology, Neoplasms/blood supply, Neoplasms/therapy, Neovascularization, Pathologic/therapy
Pubmed
Web of science
Create date
28/01/2008 8:36
Last modification date
20/08/2019 15:31
Usage data